You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

Looking Outside of the Dopamine Box: Novel Receptor Pharmacology for Schizophrenia

  • Authors: Christoph U. Correll, MD
  • CME / CE Released: 3/16/2023
  • Valid for credit through: 3/16/2024
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    Nurses - 0.50 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for psychiatrists, primary care physicians (PCPs), nurses/advanced practice nurses, nurse practitioners (NPs), physician assistants (PAs), and other clinicians who treat patients with schizophrenia.

The goal of this activity is for learners to be better able to translate the science and clinical data behind and the mechanism of action of novel muscarinic therapeutic targets for schizophrenia.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Limitations of D2 antagonism in schizophrenia treatment
    • Role of muscarinic receptors in schizophrenia pathology
  • Demonstrate greater confidence in their ability to
    • Interpret current clinical data on novel therapeutic approaches involving muscarinic receptors


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Christoph U. Correll, MD

    Professor of Psychiatry and Molecular Medicine
    The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
    New York, New York
    Professor and Chair
    Department of Child and Adolescent Psychiatry
    Charité, Universitätsmedizin Berlin
    Berlin, Germany

    Disclosures

    Christoph U. Correll, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie Inc.; ACADIA Pharmaceuticals Inc.; Allergan, Inc.; Angelini; Aristo (former); Boehringer Ingelheim Pharmaceuticals, Inc.; Cardio Diagnostics; Cerevel Therapeutics; CNX Therapeutics (former); COMPASS Pathways; Darnitsa (former); Gedeon Richter; Hikma Pharmaceuticals (former); Holmusk; Intra-Cellular Therapies, Inc.; Janssen/Johnson & Johnson; Karuna Therapeutics; LB Pharma; Lundbeck, Inc.; MedAvante-ProPhase; MedinCell; Merck; MindPax; Mitsubishi Tanabe Pharma Corporation (former); Mylan Laboratories Inc.; Neurocrine Biosciences, Inc.; Newron (former); Noven Pharmaceuticals, Inc.; Novo Nordisk; Otsuka Pharmaceutical Co., Ltd.; Pharmabrain; PPD Biotech; Recordati; Relmada Therapeutics, Inc.; Reviva Pharmaceuticals Inc.; ROVI; Seqirus; SERVIER (former); SK Life Science; Sunovion; Sun Pharmaceutical Industries, Ltd. (former); Supernus Pharmaceuticals, Inc.; Takeda; Teva; Viatris
    Speaker or member of speakers bureau for: AbbVie Inc.; Angelini; Aristo; Damitsa; Gedeon Richter; Hikma Pharmaceuticals; Intra-Cellular Therapies, Inc; Janssen/Johnson & Johnson; Lundbeck, Inc.; Mitsubishi Tanabe Pharma Corporation; Mylan Laboratories Inc.; Otsuka Pharmaceutical Co., Ltd.; Recordati; Seqirus; Sunovion; Takeda; Viatris
    Research funding from: Janssen; Takeda
    Stock options from: Cardio Diagnostics; LB Pharma; Mindpax; Quantic

Editor

  • Lisette Arnaud-Hevi, PhD

    Senior Medical Education Director, Medscape, LLC

    Disclosures

    Lisette Arnaud-Hevi, PhD, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

Looking Outside of the Dopamine Box: Novel Receptor Pharmacology for Schizophrenia

Authors: Christoph U. Correll, MDFaculty and Disclosures

CME / CE Released: 3/16/2023

Valid for credit through: 3/16/2024

processing....

Educational Impact Challenge

The goal of this activity is for learners to be better able to translate the science and clinical data behind and the mechanism of action of novel muscarinic therapeutic targets for schizophrenia.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print